New hope for rare leukemia: aggressive combo therapy shows promise

NCT ID NCT02858999

Completed Disease control Sponsor: Centre Hospitalier Universitaire, Amiens Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This phase 2 trial tested a powerful combination of chemotherapy drugs followed by stem cell transplants in 40 patients under 70 with primary plasma cell leukemia, a rare and aggressive blood cancer. The goal was to see if this intensive approach could improve how long patients live without the disease coming back. The study also collected blood and bone marrow samples to better understand the disease.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: combination chemotherapy (bortezomib, dexamethasone, doxorubicin, cyclophosphamide) followed by stem cell transplant
What this could lead to: If successful, this approach could improve disease-free survival and offer a more effective treatment strategy for this rare and aggressive blood cancer.
What could go wrong: This is a small, early-phase trial with only 40 participants, so results may not apply to all patients. The intensive treatment carries significant risks, including side effects from chemotherapy and transplant complications.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

plasma cell leukemia plasma cell myeloma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

MULTIPLE MYELOMA

Contacts and locations

Locations

AP-HP

Paris, 75004, France
CH Dunkerque

Dunkirk, 59385, France
CH Pays d'Aix

Aix-en-Provence, 13616, France
CHRU Lille

Lille, 59037, France
CHU Amiens

Amiens, 80054, France
CHU Besançon

Besançon, 25030, France
CHU Caen

Caen, 14033, France
CHU Clermont Ferrand

Clermont-Ferrand, 63003, France
CHU Dijon

Dijon, 21034, France
CHU Nancy

Nancy, 54035, France
CHU Nantes

Nantes, 44093, France
CHU Nice

Nice, 06003, France
CHU Poitiers

Poitiers, 86021, France
CHU Rennes

Rennes, 35033, France
CHU Strasbourg

Strasbourg, 67091, France
CHU Toulouse

Toulouse, 31059, France
CHU Tours

Tours, 37044, France
Hospices Civils de Lyon

Lyon, 69229, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.